Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success?

In this issue of Cancer Immunology Research, Ferris and colleagues demonstrate that type 1 conventional DC (cDC1) vaccines drive tumor rejection through direct antigen presentation, without the need of endogenous cDC1. This suggests that cDC1-based vaccines could represent an optimal strategy to induce antitumor immunity in patients. See related article by Ferris et al., (7).

• Publication year

  2022

• Venue

  Cancer immunology research

• Publication date

  2022-07-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-22-0473PMID 35802596
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1.

  2022cited by this paper
• The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy

  2021cited by this paper
• Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells.

  2020cited by this paper
• cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity

  2020cited by this paper
• Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.

  2018cited by this paper
• CD8+ T Cell Priming by Dendritic Cell Vaccines Requires Antigen Transfer to Endogenous Antigen Presenting Cells

  2010cited by this paper
• Endogenous Dendritic Cells Are Required for Amplification of T Cell Responses Induced by Dendritic Cell Vaccines In Vivo 1

  2003cited by this paper

• Human dendritic cell subsets in the glioblastoma-associated microenvironment.

  2023cites this paper